ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Neuron-glioma synaptic transmission amplified by free 19S proteasome-mediated AMPAR deubiquitination promotes tumor progression.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma progression is closely linked to neuronal activity. Glutamatergic neurons form functional synapses with glioma cells (neuron-glioma synapses, NGS), directly promoting tumor growth via electrophysiological signaling. However, the key molecular regulators of NGS remain unclear. This study aims to investigate the pivotal role of free 19S proteasomes in NGS and their underlying molecular mechanisms. Combining a murine orthotopic glioma model with an in vitro NGS model, we demonstrate specific enrichment of free 19S proteasomes within tumor-infiltrated regions. These proteasomes maintain the stability of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPARs) through their deubiquitination activity, thereby enhancing synaptic signal transmission and fostering tumor progression. Functionally, inhibition of free 19S deubiquitinase activity significantly attenuates postsynaptic potentials and suppresses tumor proliferation and invasion. Interestingly, radiotherapy further activates the free 19S-AMPAR axis, suggestive of a promising strategy to enhance radiosensitivity by targeting this pathway. In therapeutic experiments using mouse models, combined inhibition of the 19S-AMPAR axis and radiotherapy markedly suppressed growth of glioma. These findings elucidate a novel mechanism of glioma-neuron interaction via proteasome-mediated synaptic regulation and provide a crucial foundation for developing combination therapies targeting synaptic pathways. This study uncovers a new function of proteasomes in intercellular communication, offering a potential target to overcome glioma treatment resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.